David Chang

Professor of Surgical Oncology

University of Glasgow

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom Professors in Cancer Biology Cancer Biology professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

David Chang is a Professor of Surgical Oncology at the University of Glasgow, UK. His research primarily focuses on pancreatic cancer, exploring areas such as DNA damage response, therapeutic sensitivity, and the role of cancer-associated fibroblasts. His recent publications include studies on overcoming resistance to DNA damaging agents and identifying molecular subtypes of pancreatic cancer recurrence.

Articles (12)

Year:

2025

Year:

2025

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (9)

Oliver Hofmann

Associate Professor

University of Melbourne

AUSTRALIA

View details

Adam Bryce

University of Glasgow

UNITED KINGDOM

View details

Assya Legrini

University of Glasgow

UNITED KINGDOM

View details

Hans Joachim Herrmann

Head of Clinical Nutrition

University Hospital

GERMANY

View details

Christian Pilarsky

Professor

Universitätsklinikum Erlangen

GERMANY

View details

Chiara Braconi

University of Glasgow

UNITED KINGDOM

View details

Colin Rae

University of Glasgow

UNITED KINGDOM

View details

Thomas Caulfield

Professor

Mayo Clinic Research Florida

UNITED STATES

View details

Brooke Pereira

Conjoint Lecturer

UNSW Sydney

AUSTRALIA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

David Chang

Research Interests

Explore related searches

Contact this professor

About

Articles (12)

Sequential ATR and PARP inhibition overcomes acquired DNA damaging agent resistance in pancreatic ductal adenocarcinoma

KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition

ReProMSig: an integrative platform for development and application of reproducible multivariable models for cancer prognosis supporting guideline-based transparent reporting

Genomic and Molecular Analyses Identify Molecular Subtypes of Pancreatic Cancer Recurrence

Exploring the Biology of Cancer-Associated Fibroblasts in Pancreatic Cancer

Spatial expression of IKK-alpha is associated with a differential mutational landscape and survival in primary colorectal cancer

ICGC-ARGO precision medicine: familial matters in pancreatic cancer.

Muscle-Derived Cytokines Reduce Growth, Viability and Migratory Activity of Pancreatic Cancer Cells

ROR1 and ROR2 expression in pancreatic cancer.

Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage.

Role of PLEXIND1/TGFβ Signaling Axis in Pancreatic Ductal Adenocarcinoma Progression Correlates with the Mutational Status of KRAS

Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis.

Collaborators (9)

Oliver Hofmann

Adam Bryce

Assya Legrini

Hans Joachim Herrmann

Christian Pilarsky

Chiara Braconi

Colin Rae

Thomas Caulfield

Brooke Pereira

Make your next move.